BioLegacy accelerates your discovery and development programs by providing a fully integrated, end-to-end pharmacology service designed to deliver definitive efficacy data. Our deep expertise spans a vast portfolio of validated in vivo models across multiple therapeutic areas and a comprehensive range of species, from rodents to non-human primates. Our advanced, in-house bioanalytical capabilities elucidate complex pharmacokinetic and pharmacodynamic relationships. Our operational agility ensures that studies are initiated quickly and executed efficiently. Our flexibility enables everything from rapid, non-GLP efficacy screening to pivotal, GLP-compliant safety pharmacology studies required for your IND.
One of BioLegacy’s core strengths is our extensive portfolio of well-characterized in vivo efficacy models across a wide range of human diseases. Our PhD-level study directors, each an expert in their specific therapeutic area, leverage these translatable systems to help you demonstrate proof-of-concept, evaluate efficacy, and elucidate your therapeutic’s mechanism of action. By selecting the most scientifically relevant model, we ensure the generation of robust, decision-driving data that builds a strong foundation for your IND program.
A comprehensive understanding of a compound’s exposure-response relationship is critical for successful clinical translation. BioLegacy’s PK/PD studies are designed and executed to provide a clear picture of what your drug does to the body and what the body does to your drug. This essential data is used to establish therapeutic index, guide dose selection for IND-enabling or first-in-human studies, and provide the mechanistic link between drug concentration and biological effect.
Robust in vivo pharmacology is supported by BioLegacy’s state-of-the-art, in-house bioanalytical capabilities, ensuring seamless integration and rapid data turnaround. Our laboratories are equipped with advanced platforms to provide precise, quantitative data from a wide range of biological matrices. This allows for a deep, mechanistic understanding of your compound’s activity and provides the unimpeachable data quality you need for studies from exploratory research to regulated, IND-enabling, GLP preclinical trials.
See why BioLegacy is one of the fastest growing CROs in the United States.